Ειδήσεις: D. BORAL CAPITAL | PXAI

Version	Description	Date
8.42	[ADDED SOURCE REGISTRY LIST VIEW]	04/03/2026 16:19
8.41	[LOCALIZED INDEX.PHP MENU AND MODALS TO US ENGLISH]	04/03/2026 16:11
8.40	[TRANSLATED FRONTEND TO US ENGLISH]	04/03/2026 16:10
8.41	[RESTORED DETAILED SOURCES VIEW (ARTICLES + EVENTS) IN US ENGLISH]	04/03/2026 15:50
8.41	[RESTORED DETAILED SOURCES VIEW (ARTICLES + EVENTS) IN US ENGLISH]	04/03/2026 15:46
8.40	[REVERTED TO STANDARD TABLE LAYOUT (US ENGLISH)]	04/03/2026 15:40
8.39	[FIXED DB CONNECTION SCOPE IN SOURCES LOGIC]	04/03/2026 15:38
8.38	[TRANSLATED SOURCES VIEW TO US ENGLISH]	04/03/2026 15:01
8.37	[FULL FRONTEND TRANSLATION (MENU, FEED, COMMENTS, TTS) TO US ENGLISH.]	04/03/2026 14:58
8.67	[MANUAL OVERRIDE OF GREEK MENU ITEMS]	04/03/2026 13:36
8.66	[NGINX OPTIMIZED MENU FIX]	04/03/2026 13:33
8.65	[FIXED GREEK MENU ITEMS]	04/03/2026 13:32
8.60	[MENU & UI LOCALIZATION TO US ENGLISH]	04/03/2026 13:30
8.50	[FULL TRANSLATION TO US ENGLISH]	04/03/2026 13:27
9.75	[INJECTED EVENT FUSION_SUMMARY INTO FEED LOOPS TO DISPLAY AI TAGS CORRECTLY]	26/02/2026 14:44

25/03 08:52 defenseworld.net

Compass Therapeutics (NASDAQ:CMPX) Given “Buy” Rating at Guggenheim

Compass Therapeutics CMPX buy rating price target Guggenheim D. Boral Capital

25/03 08:18 defenseworld.net

Vertical Aerospace (NYSE:EVTL) Receives Buy Rating from D. Boral Capital

Vertical Aerospace EVTL D. Boral Capital buy rating analyst sentiment stock target

20/03 08:48 defenseworld.net

Plus Therapeutics (NASDAQ:PSTV) Receives “Buy” Rating from D. Boral Capital

Plus Therapeutics PSTV analyst ratings buy sell target price

19/03 10:16 defenseworld.net

CervoMed (NASDAQ:CRVO) Price Target Raised to $21.00 at Chardan Capital

CervoMed CRVO price target brokerage ratings Chardan Capital D. Boral Capital

19/03 09:22 defenseworld.net

Trevi Therapeutics’ (TRVI) Buy Rating Reaffirmed at D. Boral Capital

Trevi Therapeutics buy rating target price biotech D. Boral Capital Leerink Partners

19/03 09:22 defenseworld.net

Trevi Therapeutics’ (TRVI) Buy Rating Reaffirmed at D. Boral Capital

Trevi Therapeutics buy rating target price biotech D. Boral Capital Leerink Partners

Loading...